علاج الهيموفيليا A الشديدة مع مثبطات عامل التخثر الثامن لدى المرضى الخاضعين لإجراء طبي غازي

References

DOI: 10.1016/j.jtha.2024.05.026

• In individuals with severe hemophilia A with inhibitors undergoing invasive procedures requiring treatment with bypassing agents, the ISTH Hemophilia Guideline Panel suggests either recombinant FVIIa (eptacog alfa) or activated prothrombin complex concentrate (conditional recommendation, based on very low–certainty evidence ⨁◯◯◯).
• In patients who are on prophylaxis with emicizumab, recombinant FVIIa is preferred due to potential thrombotic complications with concomitant use of emicizumab and activated prothrombin complex concentrate.